Handelsbanken Fonder AB Acquires Shares of 53,200 Dyne Therapeutics, Inc. $DYN

Key Points

• Handelsbanken Fonder AB acquired 53,200 shares of Dyne Therapeutics valued at approximately $1.18 million. Institutional investors collectively own 96.68% of the company.
• Analysts have a consensus “Moderate Buy” rating with a $34.42 target price, compared with the stock’s reported $26.00 price. Price targets range from $24 to $50.
• Dyne reported a quarterly loss of $1.08 per share, wider than the expected $0.75 loss, while insiders sold substantially more stock than they purchased over the past three months, including a director’s $54 million sale.

Handelsbanken Fonder AB bought a new position in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor bought 53,200 shares of the company's stock, valued at approximately $1,182,000.

Other institutional investors also recently modified their holdings of the company. Hilton Head Capital Partners LLC bought a new stake in Dyne Therapeutics during the first quarter worth about $26,000. Strs Ohio purchased a new position in shares of Dyne Therapeutics during the fourth quarter valued at approximately $51,000. Aster Capital Management DIFC Ltd bought a new stake in shares of Dyne Therapeutics in the 4th quarter worth approximately $84,000. Steward Partners Investment Advisory LLC grew its stake in shares of Dyne Therapeutics by 102.1% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company's stock worth $95,000 after buying an additional 2,465 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its stake in shares of Dyne Therapeutics by 275.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 10,495 shares of the company's stock worth $100,000 after buying an additional 7,697 shares during the last quarter. 96.68% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have issued reports on DYN. Sanford C. Bernstein lifted their price objective on Dyne Therapeutics from $23.00 to $24.00 and gave the company a "market perform" rating in a research note on Wednesday, May 13th. Morgan Stanley cut their target price on Dyne Therapeutics from $47.00 to $45.00 and set an "overweight" rating on the stock in a research note on Friday, July 31st. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Dyne Therapeutics in a research report on Friday, July 17th. Evercore set a $33.00 price target on shares of Dyne Therapeutics in a research note on Friday, May 15th. Finally, HC Wainwright reissued a "buy" rating and set a $50.00 price objective on shares of Dyne Therapeutics in a research report on Monday. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Dyne Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $34.42.

Dyne Therapeutics Stock Performance

Shares of NASDAQ DYN opened at $26.00 on Wednesday. The company has a quick ratio of 12.02, a current ratio of 12.02 and a debt-to-equity ratio of 0.28. Dyne Therapeutics, Inc. has a 52-week low of $11.65 and a 52-week high of $27.31. The company has a market cap of $4.86 billion, a PE ratio of -7.81 and a beta of 1.07. The firm's 50-day moving average price is $23.18 and its 200-day moving average price is $19.61.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last announced its earnings results on Thursday, July 30th. The company reported ($1.08) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.33). As a group, analysts anticipate that Dyne Therapeutics, Inc. will post -3.37 EPS for the current year.

Insider Buying and Selling

In other Dyne Therapeutics news, Director Jason P. Rhodes sold 2,160,516 shares of the stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $25.00, for a total value of $54,012,900.00. Following the transaction, the director directly owned 428,946 shares in the company, valued at approximately $10,723,650. This trade represents a 83.43% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Brian S. Posner purchased 2,500 shares of the company's stock in a transaction dated Wednesday, June 3rd. The shares were acquired at an average price of $17.48 per share, for a total transaction of $43,700.00. Following the purchase, the director directly owned 22,500 shares in the company, valued at approximately $393,300. The trade was a 12.50% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders purchased 6,500 shares of company stock worth $114,000 and sold 4,139,196 shares worth $99,449,852. Company insiders own 9.46% of the company's stock.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company's proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne's lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.

Want to see what other hedge funds are holding DYN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source